The US Food and Drug Administration has approved Celltrion's biosimilar of Johnson & Johnson's Remicade (infliximab) - but the launch date of the blockbuster's cheaper rival remains uncertain.

Caruso said the period for the Remicade biosimilar ends early in October and there can be no launch before that. He added: “We will be vigorously defending our patent. Whether or not a ...

Experts explored the latest trends, approvals, and pipeline developments in cell and gene therapies, rare disease, immunology ...

Several of the top Branded Biologic Drugs along with their associated Biosimilar drugs include: Humira (Adalimumab); Remicade (Infliximab); Rituxan (Rituximab); Enbrel (Etanercept); Herceptin ...

A UPMC spokesperson said: "UPMC Health Plan covers both Remicade and biosimilars and we do not require members currently taking either drug to switch to the other." But Soones's medical record has ...

Biosimilar adoption is hindered by complex reimbursement structures and misaligned incentives, despite their cost-saving potential. Collaborative stakeholder efforts and leveraging electronic ...

Three months after a federal judge in West Virginia sided with Regeneron, blocking the market entry of two biosimilars for blockbuster eye disease drug Eylea, the same judge has rejected the ...

As a result of the deal, Blue Shield of California will purchase a Humira biosimilar for $525 per monthly dose, significantly below the drug’s net price of $2,100. The biosimilar will be availab ...

Shares of Regeneron fell 5% yesterday after the company’s effort to block Amgen from launching a biosimilar version of its blockbuster eye drug Eylea hit a legal roadblock. The judge ...

In India, these drugs are underutilized due to high costs and limited awareness. Biosimilars offer a more affordable alternative. JAK inhibitors treat conditions like ankylosing spondylitis but ...

Regeneron has accused Amgen's biosimilar version of Eylea of infringing dozens of its patents. U.S. District Judge Thomas Kleeh on Monday rejected Regeneron's request for a preliminary injunction ...